CoChat
Sign Up
Cited by 142Hepatitis C virus researchTreatment of Major DepressionTryptophan and brain disorders

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C

Open access
RAISON, C. L., WOOLWINE, B. J., DEMETRASHVILI, M. F., BORISOV, A. S., WEINREIB, R., STAAB, J. P., ZAJECKA, J. M., BRUNO, C. J., HENDERSON, M. A., REINUS, J. F., EVANS, D. L., ASNIS, G. M., MILLER, A. H.·2007·Alimentary Pharmacology & Therapeutics
DOI 10.1111/j.1365-2036.2007.03316.x
Open this paper in CoChat — free accountOpen PDF

Abstract

SUMMARY: Background Whether antidepressants prevent depression during interferon‐alpha/ribavirin treatment for hepatitis C virus infection has yet to be established. Aim To investigate the use of paroxetine in a prospective, double‐blind, placebo‐controlled study for this indication. Methods Sixty‐one hepatitis C virus‐infected patients were randomly assigned to the antidepressant, paroxetine (n = 28), or placebo (n = 33), begun 2 weeks before and continued for 24 weeks during interferon‐alpha/ribavirin treatment. Primary endpoints included development of major depression and severity of depressive symptoms measured by the Montgomery Asberg Depression Rating Scale (MADRS). Results Rates of major depression during the study were low (17%) and did not differ between groups. Nevertheless, using published MADRS cut‐off scores, the percent of subjects who met criteria for mild, moderate or severe depression during interferon‐alpha/ribavirin therapy was significantly lower in paroxetine‐ vs. placebo‐treated subjects (P = 0.02, Fisher’s exact test). Assignment to paroxetine was also associated with significantly reduced depressive symptom severity. This effect was largely accounted for by participants with depression scores above the median (MADRS > 3) at baseline in whom paroxetine was associated with a maximal reduction in MADRS scores of 10.3 (95% CI: 2.1–18.5) compared with placebo at 20 weeks (P < 0.01). Study limitations included a small sample size and high drop‐out rate. Conclusion This double‐blind, placebo‐controlled trial provides preliminary data in support of antidepressant pre‐treatment in hepatitis C virus patients with elevated depressive symptoms at baseline.

Overview

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2007.03316.x

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 60 references

Research works printed but not linked: 3

  1. 10.1176/appi.ps.57.4.570 · DOI
  2. Anonymous, 2005, Physicians’ Desk Reference
  3. Jacobson IM, 2005, Weight‐based ribavirin (WBD) increases sustained viral response (SVR) in patients with chronic hepatitis C (CHC): final results of the WIN‐R study, a US community based trial, Hepatol, 1, 749A

Cited by

Sorted by citations

Items 101–142 of 142

Related

See all

Metadata

Authors
RAISON, C. L., WOOLWINE, B. J., DEMETRASHVILI, M. F., BORISOV, A. S., WEINREIB, R., STAAB, J. P., ZAJECKA, J. M., BRUNO, C. J., HENDERSON, M. A., REINUS, J. F., EVANS, D. L., ASNIS, G. M., & MILLER, A. H.
Affiliations
  • Emory University (US)
  • University of Pennsylvania (US)
  • Rush University Medical Center (US)
  • Kaiser Permanente (US)
  • Albert Einstein College of Medicine (US)
Corresponding author
MILLER, A. H.
ORCID
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2007-03-20
Volume
25
Issue
10
Pages
1163-1174
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
DOI
10.1111/j.1365-2036.2007.03316.x
OpenAlex
W1482765914
Cited by
142
References
60
Citations by year
2025: 1 · 2024: 1 · 2022: 4 · 2020: 4 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 3 · 2015: 11 · 2014: 8 · 2013: 23 · 2012: 17
FWCI
10.96
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Alimentary Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Eli Lilly and Company
  • Pfizer
  • National Institutes of Health
  • National Institute of Mental Health (MH-00680, K23MH064619, MH 60723, MH 64619, R01MH060723, MH060723)
  • National Center for Research Resources (M01-RR00039, M01RR000039)
  • NIH Clinical Center
Topics
  • Health Sciences › Medicine › Hepatology › Hepatitis C virus research
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
paroxetine, antidepressant prophylaxis, depression prevention, interferon-alpha, ribavirin, hepatitis C, depressive symptoms, antiviral therapy adverse effects, Montgomery-Asberg Depression Rating Scale
MeSH terms
Adolescent, Adult, Aged, Antiviral Agents, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Female, Humans, Male, Middle Aged, Ribavirin, Interferon-alpha, Paroxetine, Hepatitis C, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review